The FemTech companies
The Boards of Directors of Peptonic and
According to the Letter of Intent, the ownership in the joint venture shall, indicatively, correspond to the following:
(a) Peptonic's holding is intended to amount to eighty-five (85) percent of the number of shares in New Peptonic.
(b)
In order to carry out the distribution as above, the Company's intention is, indicatively, that shareholders in
The planned Merger in brief
- The merger is intended to be carried out by Peptonic absorbing
Pharmiva , which will subsequently be dissolved. -
The proposed merger requires, among other things, that the Companies' boards of directors resolve to adopt a joint merger plan and that the Merger is approved by an extraordinary general meeting of
Pharmiva . No final decision on the merger will be made until the union negotiations have been completed. -
Declarations have been made with shareholders of
Pharmiva regarding the contemplated Merger, and shareholders representing more than 37 percent of the shares inPharmiva have undertaken or given their intention to vote in favour of the proposed Merger at an extraordinary general meeting, provided that the other conditions for completion of the Merger are fulfilled. - The completion of the Merger will not be dependent on any financing as the Merger Consideration will consist exclusively of new shares in Peptonic.
- More information about the Merger and the merger plan is expected to be published around the week 27 2023
- A merger document is expected to be published around week 29 2023.
Background and motive to the proposed merger
The motive of the proposed Merger is to create a powerful FemTech company with increased opportunities in the fast-growing market for intimate women's health.
Comment from Peptonic CEO
Peptonic is a FemTech company with a core business where we are building a portfolio of clinically proven intimate self-care products following the principle of diagnose, treat and prevent. Through our offer, a user should be able to manage their entire intimate health from diagnosis to treatment and the use of preventive products. The portfolio is built through a combination of acquisitions, own development and in-licensing. A merger with
Comment from
During the spring, we have worked intensively to ensure that the values built up so far in
Advisor
For further information, please contact:
Phone: +46 72 249 90 43
E-post: erik.sundquist@peptonicmedical.se
About
Peptonic is a Swedish innovative biomedical company that conducts research, development and sales of medical treatments and lifestyle products in the field of women's health. Peptonic has divided its operations into two business areas: "Medical Consumer" and "Lifestyle Consumer". The "Medical Consumer" business area is based on clinically proven intimate self-care and is the company's main focus and is sold under the VagiVital brand. The "Lifestyle Consumer" business area consists of lifestyle products with a focus on menstruation, sex and fertility and is sold under the Lunette brand. The company was founded in 2009 and the share has been traded on Spotlight (www.spotlightstockmarket.com) in
This disclosure contains information that
https://news.cision.com/peptonic-medical-ab/r/peptonic-and-pharmiva-sign-letter-of-intent-to-merge-and-create-a-leading-intimate-women-s-health-co,c3787926
https://mb.cision.com/Main/11203/3787926/2131488.pdf
(c) 2023 Cision. All rights reserved., source